Headquartered in Syracuse, AptaMatrix is a privately held biotechnology company developing next-generation sequencing-based methods to accelerate the discovery of aptamers—DNA or RNA molecules that can support diagnostic and biosensor applications. Its patented Acyclic Identification of Aptamers (AIA) and multiplexed AIA approaches grew from research and industry partnerships at Syracuse University, with the company applying them to disease detection and its AP3 assay platform. AptaMatrix also developed AlloSwitch sensors for near-real-time detection of biological targets.
AptaMatrix Sexual Harassment Prevention Policy
Compliance program
Financial Conflict of Interest (FCOI)
Compliance program
Applied BioPhysics, IncFounded in 1991 by the inventors of Electric Cell-substrate Impedance Sensing, Applied BioPhysics manufactures ECIS® instruments and electrode arrays that monitor living cells in tissue culture in real time. Based in Troy, New York, the company applies biophysical research to cell research and drug discovery, with 95 percent of its products made at its U.S. facility. Its systems give researchers a label-free way to study cell behavior while maintaining active connections with the academic community that helped shape the technology.TROY, NY
PhlotonicsPhlotonics develops light-powered biosensors that measure biological activity for advanced biomanufacturing and drug discovery. Founded around a core technology co-developed by its three PhD co-founders, the Rochester company applies photonics to real-time bioprocess monitoring, with peer-reviewed studies supporting its approach.ROCHESTER, NY
Scanogen IncBaltimore-based Scanogen develops molecular diagnostic systems that detect infectious-disease biomolecules directly from body fluids, using its proprietary Single Molecule And Rapid Tethering (SMART) technology. The company is focused on a sample-to-answer platform for point-of-care testing, including an assay designed to identify bloodstream-infection pathogens from whole blood within two hours. Scanogen has received more than $20 million in NIH grants and collaborates with Johns Hopkins University and federal agencies in the Washington, D.C., area.BALTIMORE, MD
AUM LifeTech, IncPhiladelphia-based AUM LifeTech develops RNA-targeting therapeutics through its proprietary AUM silence antisense oligonucleotide platform, which is designed to silence or regulate disease-linked RNA without an external delivery vehicle. Founded by biotechnology entrepreneur Veenu Aishwarya, the company is pursuing preclinical treatments for genetically defined diseases, including an anti-FOXP3 cancer-immunotherapy program developed with Children’s Hospital of Philadelphia. Its work also includes a Parkinson’s disease program conducted with the University of Pennsylvania.PHILADELPHIA, PA